Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 40Terminated 12Unknown 11Recruiting 5Active not recruiting 3Withdrawn 2Suspended 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Wounds and Injuries 1Ulcer 1Skin Ulcer 1Chronic Pain 1Cancer Pain 1Adenocarcinoma 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Morphine × Clear all
NCT05325164 2022-12-05

METHADOPT

Ottawa Hospital Research Institute

Phase 3 Withdrawn

Cancer Pain, Adenocarcinoma, Neoplasms

NCT00306020 2012-07-04

Analgesia and Wound Healing Assessment Following Topical Morphine Applied to Patients With Cutaneous Cancer Related Pain

Soroka University Medical Center

Phase NA Withdrawn

Neoplasms, Skin Ulcer, Ulcer, Wounds and Injuries, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡